Clinical trials and drug promotion: Selective reporting of study 329

2008/01/01 by Jon Jureidini, Leemon B. McHenry, Peter Mansfield · 7 citations
Pharmacology, Toxicology and Pharmaceutics · Decision Sciences · Medicine · #Pharmaceutical industry and healthcare #Meta-analysis and systematic reviews #Pharmaceutical studies and practices

paper · doi:10.3233/jrs-2008-0426

openalex publication_date 2008/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/06/11

Abstract

Selective reporting is prevalent in the medical literature, particularly in industry-sponsored research. In this paper, we expose selective reporting that is not evident without access to internal company documents. The published report of study 329

Citations

• Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials
• Efficacy of Paroxetine in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial

Cited by

• Industry-Sponsored Ghostwriting in Clinical Trial Reporting: A Case Study
• Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence
• Restoring invisible and abandoned trials: a call for people to publish the findings
• The illusion of evidence based medicine
• Journal of the American Academy of Child and Adolescent Psychiatry [wikipedia]
• Leemon McHenry [wikipedia]
• Study 329 [wikipedia]